Mosanna is a Swiss Biotech company developing an NCE called MOS-118 to treat Sleep Apnea, a highly prevalent disorder with a high rate of deadly commodities. The company's ambition is to offer an alternative to patients not getting a full night's treatment with the current standard of care. The nightly sleep disruptions accumulate over time resulting in severe adverse cardiometabolic health outcomes. The company took over the program of MOS-118 from Sanofi, including substantial clinical experience with the compound, significantly de-risking further development. MOS-118 is IND ready except for some on-going CMC optimization and expected to be clinically tested within a year. The company is seeking a complementing investment after a lead investor has helped to start the venture earlier this year.